Table 2.

[¹⁴C]Valine accumulation and incorporation into protein in control and portacaval-shunted rats

Treatment	n	Body wt. (g)	TCA-soluble fraction (nCi/g wet wt./h)						Valine incorporation into protein a (pCi/mg dry wt. protein/h)
			Brain		Liver		Kidney		Brain		Liver		Kidney
				%		%		%		%		%		%
Control	7	381 ± 14	3.8 ± 0.2	100	14.1 ± 0.6	100	13.5 ± 0.8	100	4.1 ± 0.3	100	15.8 ± 1.3	100	12.4 ± 0.9	100
PC-shunt
3 days	5	237 ± 7	7.8 ± 0.4b	205	19.8 ± 1.1	140	13.4 ± 0.8	99	4.5 ± 0.1	110	25.7 ± 0.8b	162	16.5 ± 0.9a	133
2 weeks	4	272 ± 72	(5.4 ± 0.6a)c	(142)	23.9 ± 6.2	170	11.8 ± 0.9	87	(5.8 ± 0.3b)c	(141)	34.4 ± 1.4b	218	17.0 ± 1.6a	137
8 weeks	5	422 ± 28	5.6 ± 0.4a	147	16.5 ± 1.4	117	13.2 ± 0.5	98	4.0 ± 0.1	98	24.3 ± 1.8a	154	13.8 ± 0.5	111
12 weeks	5	407 ± 30	6.0 ± 0.2a	158	36.9 ± 4.8a	262	14.7 ± 1.1	109	4.7 ± 0.2	115	21.8 ± 0.6a	138	13.8 ± 0.2	111

Rats were injected intraperitoneally with L-[1-¹⁴C]valine (7.5 mmol/kg, 2.66 µCi/mmol) at intervals after portacaval (PC) shunting, and the label in the precursor pool (TCA-soluble fraction) and protein determined 1h later (see Methods). Values are means ± SD; percentages of respective control values were calculated with mean values.

^aP<0.05,

^bP<0.01 vs. control, ANOVA and Dunnett’s test.

^cValues for brain in 2-week shunts were for cerebral cortex; all others represent whole brain.